{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:40:45Z","timestamp":1793328045271,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004562","name":"Minist\u00e8re de l'Enseignement sup\u00e9rieur et de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omtn.2026.102834","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:05:57Z","timestamp":1768291557000},"page":"102834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving angiogenesis ameliorates the efficacy of ASO-based exon skipping for the treatment of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"37","author":[{"given":"Mathilde","family":"Blitek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Doisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Le Coz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xaysongkhame","family":"Phongsavanh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Ben Aicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Rotini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-1165","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Goyenvalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102834_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omtn.2026.102834_bib2","doi-asserted-by":"crossref","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne Muscular Dystrophy: From Diagnosis to Therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2026.102834_bib3","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102834_bib4","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102834_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-020-01363-3","article-title":"Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders","volume":"80","author":"Bizot","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.102834_bib6","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omtn.2026.102834_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102834_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102834_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.102834_bib10","series-title":"Muscular Dystrophy Therapeutics Methods in Molecular Biology","first-page":"31","article-title":"Viltolarsen: From Preclinical Studies to FDA Approval","author":"Roshmi","year":"2023"},{"key":"10.1016\/j.omtn.2026.102834_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41467-017-00924-7","article-title":"Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle","volume":"8","author":"Novak","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102834_bib12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2026.102834_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2026.102834_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.102834_bib15","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtn.2026.102834_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/nar\/gkab1199","article-title":"Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides","volume":"50","author":"Relizani","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102834_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102834_bib18","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1039\/D4MD00394B","article-title":"The bench to bedside journey of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophy","volume":"15","author":"Blitek","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.omtn.2026.102834_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/nat.2024.0085","article-title":"Combined 20-Hydroxyecdysone and Antisense-Mediated Exon Skipping Improve Functional Outcomes in a Mouse Model of Duchenne Muscular Dystrophy","volume":"35","author":"Blitek","year":"2025","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102834_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0022-510X(87)90007-4","article-title":"Vascular endothelial cell injury and platelet embolism in Duchenne muscular dystrophy at the preclinical stage","volume":"82","author":"Miike","year":"1987","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omtn.2026.102834_bib21","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.ajpath.2015.05.009","article-title":"Structural and Functional Alterations of Skeletal Muscle Microvasculature in Dystrophin-Deficient mdx Mice","volume":"185","author":"Latroche","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2026.102834_bib22","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00018-019-03006-7","article-title":"Targeting angiogenesis in Duchenne muscular dystrophy","volume":"76","author":"Podkalicka","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtn.2026.102834_bib23","doi-asserted-by":"crossref","first-page":"13818","DOI":"10.1073\/pnas.250379497","article-title":"Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy","volume":"97","author":"Sander","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102834_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/biomedicines9050481","article-title":"Age-Dependent Dysregulation of Muscle Vasculature and Blood Flow Recovery after Hindlimb Ischemia in the mdx Model of Duchenne Muscular Dystrophy","volume":"9","author":"Podkalicka","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2026.102834_bib25","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1161\/ATVBAHA.112.301172","article-title":"Angiogenic Impairment of the Vascular Endothelium: A Novel Mechanism and Potential Therapeutic Target in Muscular Dystrophy","volume":"33","author":"Palladino","year":"2013","journal-title":"ATVB"},{"key":"10.1016\/j.omtn.2026.102834_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102834_bib27","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.omtn.2026.102834_bib28","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1096\/fj.07-8459com","article-title":"VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice","volume":"21","author":"Messina","year":"2007","journal-title":"FASEB j"},{"key":"10.1016\/j.omtn.2026.102834_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fphys.2014.00050","article-title":"Angiogenesis as a novel therapeutic strategy for Duchenne muscular dystrophy through decreased ischemia and increased satellite cells","volume":"5","author":"Shimizu-Motohashi","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omtn.2026.102834_bib30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/01.CIR.102.8.898","article-title":"VEGF Gene Delivery to Myocardium: Deleterious Effects of Unregulated Expression","volume":"102","author":"Lee","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2026.102834_bib31","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","volume":"108","author":"Rajagopalan","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2026.102834_bib32","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/1878-0261.13401","article-title":"A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma","volume":"17","author":"Montemagno","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omtn.2026.102834_bib33","doi-asserted-by":"crossref","first-page":"E207","DOI":"10.2527\/jas.2007-0473","article-title":"Defining the transcriptional signature of skeletal muscle stem cells","volume":"86","author":"Yablonka-Reuveni","year":"2008","journal-title":"J. Anim. Sci."},{"key":"10.1016\/j.omtn.2026.102834_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.102834_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3233\/JND-200548","article-title":"Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls","volume":"8","author":"Mendell","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2026.102834_bib36","first-page":"6045","article-title":"Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates","volume":"47","author":"\u00d8stergaard","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102834_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13691","article-title":"Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches","volume":"16","author":"Li","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtn.2026.102834_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/biomedicines6020051","article-title":"Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics","volume":"6","author":"McClorey","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2026.102834_bib39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.omtn.2023.06.022","article-title":"The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of neuromuscular disorders","volume":"33","author":"Li","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102834_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107292","article-title":"Advances in the pharmaceutical development of antibody-oligonucleotide conjugates","volume":"215","author":"Li","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.omtn.2026.102834_bib41","doi-asserted-by":"crossref","first-page":"11401","DOI":"10.1093\/nar\/gkac641","article-title":"Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice","volume":"50","author":"Desjardins","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102834_bib42","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody\u2013oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102834_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf241","article-title":"AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy","volume":"53","author":"Etxaniz","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102834_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.102834_bib45","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.102834_bib46","series-title":"FDA Investigating Deaths Due to Acute Liver Failure in Non-ambulatory Duchenne Muscular Dystrophy Patients","year":"2025"},{"key":"10.1016\/j.omtn.2026.102834_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7037786","article-title":"Targeting the Ang2\/Tie2 Axis with Tanshinone IIA Elicits Vascular Normalization in Ischemic Injury and Colon Cancer","volume":"2021","author":"Zou","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.omtn.2026.102834_bib48","doi-asserted-by":"crossref","first-page":"F1265","DOI":"10.1152\/ajprenal.00260.2019","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease","volume":"317","author":"Qian","year":"2019","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.omtn.2026.102834_bib49","first-page":"9112","article-title":"Duchenne muscular dystrophy: preliminary experience with sacubitril-valsartan in patients with asymptomatic left ventricular dysfunction","volume":"24","author":"Lamendola","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2026.102834_bib50","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jacc.2004.09.078","article-title":"Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy","volume":"45","author":"Duboc","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.omtn.2026.102834_bib51","doi-asserted-by":"crossref","first-page":"812","DOI":"10.21037\/jtd-22-1528","article-title":"Cardioprotective medication in Duchenne muscular dystrophy: a single-centre cohort study","volume":"15","author":"Kisel","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.omtn.2026.102834_bib52","article-title":"A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy","volume":"5","author":"Allen","year":"2013","journal-title":"PLoS Curr."},{"key":"10.1016\/j.omtn.2026.102834_bib53","series-title":"SUMIC: A Simple Ultrafast Multicolor Immunolabelling and Clearing Approach for Whole-Organ and Large Tissue 3D Imaging","author":"Biswas","year":"2021"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126000053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126000053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:17:22Z","timestamp":1780103842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126000053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162253126000053"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102834","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving angiogenesis ameliorates the efficacy of ASO-based exon skipping for the treatment of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102834"}}